Preclinical evaluation of macrophage reprogramming in treatment of CTCL (ASH 2025) - Nov 4, 2025 - Abstract #abs25-15400; 5347; Pres time: Dec 8, 2025; 06:00 PM - 08:00 PM; Location: OCCC - West Halls B3-B4; "Our data suggest that TLR4 inhibition and CD206 activation in the CTCL tumormicroenvironment inhibit tumor growth by inducing a shift from tumor-promoting to tumor-suppressivemacrophages. Therefore, CD206 binding peptide, RP-832c, and small molecule TLR4 inhibitor, TAK-242,present promising therapeutic options in CTCL."
IO biomarker • Preclinical • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • CD86 • MRC1 • TLR4 • TNFA
|
|
Madeline Williams1; PyungHun Park1; Carla Portocarrero1; Anjali Mishra2; Neda Nikbakht1
|